• +1-646-491-9876
    • +91-20-67278686

    Search

    Human cytomegalovirus 65 kDa Phosphoprotein-Pipeline Review H2 2017

    Human cytomegalovirus 65 kDa Phosphoprotein-Pipeline Review H2 2017

    • Report Code ID: RW00011060476
    • Category Life Sciences
    • No. of Pages 51
    • Publication Month Sep-17
    • Publisher Name Global Markets Direct
    Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83)-Pipeline Review, H2 2017

    Summary

    Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The latest report Human cytomegalovirus 65 kDa Phosphoprotein-Pipeline Review, H2 2017, outlays comprehensive information on the Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

    Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83)-65-kDa cytosolic phosoprotein (pp65) counteracts the host antiviral immune response when activated and phosphorylated and by preventing IRF3 from entering the nucleus. It participates in the transactivation of viral major immediate-early genes by the recruitment of host IFI16 to the promoter pf these genes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 3, 1, 2 and 2 respectively. Similarly, the universities portfolio in Phase II stages comprises 1 molecules, respectively. Report covers products from therapy areas Infectious Disease, Oncology and Immunology which include indications Cytomegalovirus (HHV-5) Infections, Glioblastoma Multiforme (GBM), Brain Tumor, Hematological Tumor, Human Immunodeficiency Virus (HIV) Infections (AIDS), Kidney Transplant Rejection and Liver Transplant Rejection.

    Furthermore, this report also reviews key players involved in Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    -The report provides a snapshot of the global therapeutic landscape for Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83)
    -The report reviews Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    -The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    -The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    -The report reviews key players involved in Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics and enlists all their major and minor projects
    -The report assesses Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    -The report summarizes all the dormant and discontinued pipeline projects
    -The report reviews latest news and deals related to Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) targeted therapeutics

    Reasons to buy

    -Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    -Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    -Identify and understand the targeted therapy areas and indications for Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83)
    -Identify the use of drugs for target identification and drug repurposing
    -Identify potential new clients or partners in the target demographic
    -Develop strategic initiatives by understanding the focus areas of leading companies
    -Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    -Devise corrective measures for pipeline projects by understanding Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) development landscape
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    Table of Contents 2
    List of Tables 4
    List of Figures 4
    Introduction 5
    Global Markets Direct Report Coverage 5
    Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83)-Overview 6
    Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83)-Therapeutics Development 7
    Products under Development by Stage of Development 7
    Products under Development by Therapy Area 8
    Products under Development by Indication 9
    Products under Development by Companies 10
    Products under Development by Universities/Institutes 12
    Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83)-Therapeutics Assessment 14
    Assessment by Route of Administration 14
    Assessment by Molecule Type 16
    Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83)-Companies Involved in Therapeutics Development 18
    Astellas Pharma Inc 18
    Hookipa Biotech AG 18
    Immunomic Therapeutics Inc 18
    Vakzine Projekt Management GmbH 19
    Vaximm AG 19
    VBI Vaccines Inc 20
    Vical Inc 20
    Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83)-Drug Profiles 21
    ASP-0113-Drug Profile 21
    Product Description 21
    Mechanism Of Action 21
    R&D Progress 21
    Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections-Drug Profile 24
    Product Description 24
    Mechanism Of Action 24
    R&D Progress 24
    Cellular Immunotherapy to Target PP65 for Glioblastoma Multiforme-Drug Profile 25
    Product Description 25
    Mechanism Of Action 25
    R&D Progress 25
    CyMVectin-Drug Profile 26
    Product Description 26
    Mechanism Of Action 26
    R&D Progress 26
    HB-101-Drug Profile 28
    Product Description 28
    Mechanism Of Action 28
    R&D Progress 28
    PepVax-Drug Profile 30
    Product Description 30
    Mechanism Of Action 30
    R&D Progress 30
    Triplex-Drug Profile 32
    Product Description 32
    Mechanism Of Action 32
    R&D Progress 32
    VBI-1901-Drug Profile 34
    Product Description 34
    Mechanism Of Action 34
    R&D Progress 34
    VPM-2001-Drug Profile 36
    Product Description 36
    Mechanism Of Action 36
    R&D Progress 36
    VXM-65-Drug Profile 37
    Product Description 37
    Mechanism Of Action 37
    R&D Progress 37
    Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83)-Dormant Products 38
    Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83)-Discontinued Products 39
    Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83)-Product Development Milestones 40
    Featured News & Press Releases 40
    Aug 28, 2017: VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at The Immuno-Oncology Summit 40
    Aug 15, 2017: VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for VBI-1901 to Treat Glioblastoma Multiforme 40
    May 04, 2017: Hookipa Biotech Presents Positive Data from Phase 1 First-In-Human Trial of Vaccine Against Cytomegalovirus 41
    Apr 05, 2017: VBI Vaccines to Present Update on VBI-1901 at the World Vaccine Congress 41
    Jan 09, 2017: Hookipa Biotech Announces Publication in Clinical and Vaccine Immunology Highlighting Vaxwave as an Effective Viral Vector for Vaccination against Congenital Cytomegalovirus Infections 42
    Nov 10, 2016: VBI Vaccines to Present at the Society of Neuro-Oncology Annual Meeting 42
    Oct 28, 2016: Data from Phase 1 Trial of Triplex Vaccine for Control of Cytomegalovirus Published in Blood 43
    Oct 11, 2016: VBI Vaccines Completes Pre-IND Meeting for its Glioblastoma Immunotherapy Candidate 44
    Oct 05, 2016: VBI Vaccines to Present at the World Vaccine Congress Europe 44
    Sep 20, 2016: Vical and Astellas Announce Topline Results from a Phase 2 Study of Investigational Cytomegalovirus Vaccine (ASP0113) in Kidney Transplant Patients 45
    Aug 29, 2016: VBI Vaccines to Present at the Immuno-Oncology Summit 45
    Jul 20, 2016: Hookipa Biotech Initiates First-in-Human Study of Cytomegalovirus Vaccine 46
    Jun 16, 2016: VBI Vaccines Announces Medulloblastoma Immunotherapy Program 46
    Mar 29, 2016: VBI To Present At The World Vaccine Congress Washington 47
    Mar 07, 2016: VBI Vaccines Presents New Data Supporting its Glioblastoma Immunotherapy Program at the Keystone Symposia Cancer Vaccines Conference 48
    Appendix 50
    Methodology 50
    Coverage 50
    Secondary Research 50
    Primary Research 50
    Expert Panel Validation 50
    Contact Us 50
    Disclaimer 51

    List of Tables
    Number of Products under Development by Stage of Development, H2 2017 7
    Number of Products under Development by Therapy Areas, H2 2017 8
    Number of Products under Development by Indication, H2 2017 9
    Number of Products under Development by Companies, H2 2017 10
    Products under Development by Companies, H2 2017 11
    Number of Products under Investigation by Universities/Institutes, H2 2017 12
    Products under Investigation by Universities/Institutes, H2 2017 13
    Number of Products by Stage and Route of Administration, H2 2017 15
    Number of Products by Stage and Molecule Type, H2 2017 17
    Pipeline by Astellas Pharma Inc, H2 2017 18
    Pipeline by Hookipa Biotech AG, H2 2017 18
    Pipeline by Immunomic Therapeutics Inc, H2 2017 19
    Pipeline by Vakzine Projekt Management GmbH, H2 2017 19
    Pipeline by Vaximm AG, H2 2017 19
    Pipeline by VBI Vaccines Inc, H2 2017 20
    Pipeline by Vical Inc, H2 2017 20
    Dormant Projects, H2 2017 38
    Discontinued Products, H2 2017 39

    List of Figures
    Number of Products under Development by Stage of Development, H2 2017 7
    Number of Products under Development by Therapy Areas, H2 2017 8
    Number of Products under Development by Top 10 Indications, H2 2017 9
    Number of Products by Routes of Administration, H2 2017 14
    Number of Products by Stage and Routes of Administration, H2 2017 14
    Number of Products by Molecule Types, H2 2017 16
    Number of Products by Stage and Molecule Types, H2 2017 16
    Astellas Pharma Inc
    Hookipa Biotech AG
    Immunomic Therapeutics Inc
    Vakzine Projekt Management GmbH
    Vaximm AG
    VBI Vaccines Inc
    Vical Inc

    Request for Sample

    Report Url https://www.reportsweb.com//human-cytomegalovirus-65-kda-phosphoprotein-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//human-cytomegalovirus-65-kda-phosphoprotein-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//human-cytomegalovirus-65-kda-phosphoprotein-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments